{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":23,"n_cols":5,"rows_kept":23,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[16,2,16,3],[17,2,17,3],[20,2,20,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910483133403321"]
[null,null,"Titolo",null,"Proteinkinase Inhibitors / / edited by Stefan Laufer"]
[null,null,"Pubbl/distr/stampa",null,"Cham : , : Springer International Publishing : , : Imprint : Springer, , 2021"]
[null,null,"ISBN",null,"3-030-68180-7"]
[null,null,"Edizione",null,"[1st ed. 2021.]"]
[null,null,"Descrizione fisica",null,"1 online resource (259 pages) : illustrations"]
[null,null,"Collana",null,"Topics in Medicinal Chemistry, , 1862-247X ; ; 36"]
[null,null,"Disciplina",null,"572.792"]
[null,null,"Soggetti",null,"Medicinal chemistry"]
[{"$nulls":4},"Proteins"]
[{"$nulls":4},"Bioorganic chemistry"]
[{"$nulls":4},"Pharmaceutical chemistry"]
[{"$nulls":4},"Medicinal Chemistry"]
[{"$nulls":4},"Protein Biochemistry"]
[{"$nulls":4},"Bioorganic Chemistry"]
[{"$nulls":4},"Pharmaceutics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"ProteinKinase-Inhibitors: A Story of Success -- Function, Structure and Topology of Proteinkinases -- Molecular Modelling -- Case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR -- Achieving high level of selectivity for kinase inhibitors -- Inhibitors of c-Jun N-terminal kinase 3 -- Exploiting kinase inhibitors for cancer treatment - An Overview of Clinical Results and Outlook -- Covalent Janus Kinase 3 Inhibitors."]
[null,null,null,"Sommario/riassunto","This book reviews the principles of design and examples of successful implementation of proteinkinase inhibitors (PKI), and offers a comprehensive and authoritative overview of the history and latest developments in the field. Chapters written by experts from industry and academia cover the function, structure and topology of Proteinkinases, molecular modelling, disclose how to achieve high level of selectivity for kinase inhibitors, and exploit kinase inhibitors for cancer treatment. Particular attention is given to Inhibitors of c-Jun N-terminal kinase 3, and to covalent Janus Kinase 3 Inhibitors. A case study on Receptor Tyrosine Kinases EGFR, VEGFR, PDGFR is also presented in this book. Given its breath, this book will appeal to "]
[{"$nulls":4},"medicinal chemists, students, researchers and professionals alike."]